133 related articles for article (PubMed ID: 31040930)
1. The combined efficacy of OTS964 and temozolomide for reducing the size of power-law coded heterogeneous glioma stem cell populations.
Sugimori M; Hayakawa Y; Tamura R; Kuroda S
Oncotarget; 2019 Mar; 10(24):2397-2415. PubMed ID: 31040930
[TBL] [Abstract][Full Text] [Related]
2. Targeting the T-Lak cell originated protein kinase by OTS964 shrinks the size of power-law coded heterogeneous glioma stem cell populations.
Sugimori M; Hayakawa Y; Koh M; Hayashi T; Tamura R; Kuroda S
Oncotarget; 2018 Jan; 9(3):3043-3059. PubMed ID: 29423027
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations.
Sugimori M; Hayakawa Y; Boman BM; Fields JZ; Awaji M; Kozano H; Tamura R; Yamamoto S; Ogata T; Yamada M; Endo S; Kurimoto M; Kuroda S
PLoS One; 2015; 10(8):e0135760. PubMed ID: 26284929
[TBL] [Abstract][Full Text] [Related]
4. SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance.
Wang Z; Xu X; Liu N; Cheng Y; Jin W; Zhang P; Wang X; Yang H; Liu H; Tu Y
Oncotarget; 2018 Jan; 9(1):192-204. PubMed ID: 29416606
[TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
Tso JL; Yang S; Menjivar JC; Yamada K; Zhang Y; Hong I; Bui Y; Stream A; McBride WH; Liau LM; Nelson SF; Cloughesy TF; Yong WH; Lai A; Tso CL
Mol Cancer; 2015 Nov; 14():189. PubMed ID: 26546412
[TBL] [Abstract][Full Text] [Related]
6. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
[TBL] [Abstract][Full Text] [Related]
7. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
[TBL] [Abstract][Full Text] [Related]
8. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of temozolomide treatment in patients with high-grade glioma.
Oshiro S; Tsugu H; Komatsu F; Ohmura T; Ohta M; Sakamoto S; Fukushima T; Inoue T
Anticancer Res; 2009 Mar; 29(3):911-7. PubMed ID: 19414327
[TBL] [Abstract][Full Text] [Related]
10. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
[TBL] [Abstract][Full Text] [Related]
11. Etoposide loaded layered double hydroxide nanoparticles reversing chemoresistance and eradicating human glioma stem cells in vitro and in vivo.
Wang Z; Liang P; He X; Wu B; Liu Q; Xu Z; Wu H; Liu Z; Qian Y; Wang S; Zhu R
Nanoscale; 2018 Jul; 10(27):13106-13121. PubMed ID: 29961791
[TBL] [Abstract][Full Text] [Related]
12. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Riva G; Butta V; Cilibrasi C; Baronchelli S; Redaelli S; Dalprà L; Lavitrano M; Bentivegna A
Oncol Rep; 2016 May; 35(5):2811-24. PubMed ID: 26986767
[TBL] [Abstract][Full Text] [Related]
14. β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
Zhu TZ; Li XM; Luo LH; Song ZQ; Gao X; Li ZQ; Su JY; Liang GB
Int J Oncol; 2014 Aug; 45(2):699-709. PubMed ID: 24841897
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
16. FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.
Cheng P; Wang J; Waghmare I; Sartini S; Coviello V; Zhang Z; Kim SH; Mohyeldin A; Pavlyukov MS; Minata M; Valentim CL; Chhipa RR; Bhat KP; Dasgupta B; La Motta C; Kango-Singh M; Nakano I
Cancer Res; 2016 Dec; 76(24):7219-7230. PubMed ID: 27569208
[TBL] [Abstract][Full Text] [Related]
17. Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models.
Valtorta S; Lo Dico A; Raccagni I; Gaglio D; Belloli S; Politi LS; Martelli C; Diceglie C; Bonanomi M; Ercoli G; Vaira V; Ottobrini L; Moresco RM
Oncotarget; 2017 Dec; 8(68):113090-113104. PubMed ID: 29348889
[TBL] [Abstract][Full Text] [Related]
18. How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models.
Ahmad M; Frei K; Willscher E; Stefanski A; Kaulich K; Roth P; Stühler K; Reifenberger G; Binder H; Weller M
J Neuropathol Exp Neurol; 2014 Nov; 73(11):1062-77. PubMed ID: 25289892
[TBL] [Abstract][Full Text] [Related]
19. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Bielecka-Wajdman AM; Lesiak M; Ludyga T; Sieroń A; Obuchowicz E
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1249-1256. PubMed ID: 28500556
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.
D'Alimonte I; Nargi E; Zuccarini M; Lanuti P; Di Iorio P; Giuliani P; Ricci-Vitiani L; Pallini R; Caciagli F; Ciccarelli R
Purinergic Signal; 2015 Sep; 11(3):331-46. PubMed ID: 25976165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
